ARTICLE | Deals
Returning to its roots, Amgen adding growth with $28.7B deal for Horizon
Acquisition bolsters inflammation, autoimmune portfolio after oncology franchise comes under pressure
December 12, 2022 11:52 PM UTC
With sales flat and its push into cancer yet to yield any major growth drivers, Amgen’s $28.7 billion acquisition of Horizon Therapeutics marks a continuation of the large cap’s return to the inflammatory and autoimmune space where it’s been most commercially successful.
The deal is also the latest — and largest — move by Amgen Inc. (NASDAQ:AMGN) to add growth via acquisitions...